The company said total revenues for Q3 2024 rose 11% from a year earlier to $3.72 billion, while GAAP diluted EPS was $11.54, up 30%, and non-GAAP diluted EPS was $12.46, up 8%.

1. 01

   The company said total revenues for Q3 2024 rose 11% from a year earlier to $3.72 billion, while GAAP diluted EPS was $11.54, up 30%, and non-GAAP diluted EPS was $12.46, up 8%.

2. 02

   Regeneron said global Dupixent net sales recorded by Sanofi rose 23% to $3.82 billion in Q3 2024, U.S. net sales of EYLEA HD and EYLEA rose 3% to $1.54 billion (including $392 million from EYLEA HD), and global Libtayo net sales rose 24% to $289 million.

3. 03

   The company repurchased common shares in Q3 2024 and recorded the cost of $738 million as Treasury Stock. It said $2.9 billion remained available for share repurchases under its program as of September 30, 2024.

4. 04

   The company updated its full-year 2024 GAAP R&D guidance to $5.055–$5.145 billion from the prior $5.020–$5.170 billion, and its GAAP SG&A guidance to $2.930–$3.020 billion from the prior $2.920–$3.060 billion.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.